Skip to content

Diet control intervention and related biomarker analysis in patients with mild cognitive impairment stage Alzheimer's disease

Diet control intervention and related biomarker analysis in patients with mild cognitive impairment stage Alzheimer's disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052766
Enrollment
Unknown
Registered
2021-11-05
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Calorie restriction group (CR group):Implementing 75% calorie of daily diet for three months

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. The elderly over 65 years; 2. According to ''(5): Diagnosis and Treatment of Mild Cognitive Impairment'' in the Chinese Dementia and Cognitive Impairment Diagnosis and Treatment Guidelines issued by the Chinese Dementia and Cognitive Impairment Writing Group in 2018, it is in line with MCI patients; 3. Voluntarily join this research; 4. Within two months before the start of the intervention, they have not taken any drugs that the investigator thinks will affect the results of this study; 5. Basic diseases that have a significant impact on life and survival without being determined by the researchers; 6. With reference to the existing evidence, MCI caused by Alzheimer's disease to the greatest extent (see the exclusion criteria section, non-Alzheimer's MCI patients will be excluded as much as possible).

Exclusion criteria

Exclusion criteria: 1. Before the start of the test, the Body Mass Index (BMI) is lower than 21; 2. Inherent eating habits, the average daily calorie intake is less than 1600 kcal/d; 3. Those who are judged to be muscular failure or sarcopenic obesity through body composition examination; 4. Those with severe digestive system diseases and those with a history of taking antibiotics within 1 month before the start of the study; 5. Those who are claustrophobic or have metal implants in their bodies and cannot undergo MRI examinations; 6. After epidemiological history investigation, it is determined that the symptoms of cognitive impairment are sudden and acute; 7. According to the investigation of epidemiological history, it is determined that there are serious sleep problems within six months, or those who frequently take sleeping drugs within six months; 8. Those with depressive symptoms; 9. Diagnosed Parkinson's disease patients; 10. Those with visual or hearing impairments; 11. There is a history of surgery within half a year; 12. Have a clear history of brain injury caused by external factors (such as brain injury caused by falls); 13. Have a clear history of stroke; 14. Those with a history of mental illness (such as bipolar affective disorder, schizophrenia, etc.) or related drug use; 15. Alcohol addicts; 16. A history of adverse drugs (dependence on morphine and related types of drugs) or drug use; 17. There is a history of long-term use of immunosuppressive agents for any organ transplantation or other reasons; 18. Have a clear history of hepatitis B, hepatitis C, syphilis and AIDS; 19. Participate in other research projects during the research period; 20. Other investigators believe that it is inappropriate to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment Scale Score;MRI assessment;Weight;

Secondary

MeasureTime frame
Intestinal flora;Aß42, p-tau and other marker proteins;

Countries

China

Contacts

Public ContactWang Fang

West China Hospital of Sichuan University

bio_wangf@163.com+86 15928015427

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026